ivanovaml commited on
Commit
71b43d2
·
verified ·
1 Parent(s): 022b239

Update README.md

Browse files
Files changed (1) hide show
  1. README.md +5 -6
README.md CHANGED
@@ -14,10 +14,10 @@ The TDP1_targetsInhibitors_CID_SID_IUPACs_functionalGroups dataset is a part of
14
 
15
  ## Dataset Details
16
 
17
- This dataset was leveraged for computatios, such as:
18
- - determne the most or least desirable functional group/fragmet that would provide an nsight for the development of TDP1 inhibitors
19
  - ML models based on IUPAC names broken down to functional names/fragments
20
- - Define the feature importance of the above mentioned ML modle and explore the proportion between active and inactive compounds which the first 10 feature
21
 
22
 
23
  ### Dataset Description
@@ -27,11 +27,10 @@ The dataset contains 101,876 rows, each representing a unique small biomolecule
27
  It includes 3 columns:
28
  - Column 1: CID (PubChem identifiers of the compounds that are TDP1 inhibitors)
29
  - Column 2: SID (PubChem identifiers of the substances that are TDP1 inhibitors)
30
- - Column 3: target: "1": The molecule is a TDP1 inhibitors; "0": The molecule is not a TDP1 inhibitors.
31
- - Column 4: IUPAC names of the considered in the study small biomolecules
32
  - Columns 5-5966: Functional groups/fragments of the small biomolecules considered in the study, which are the results of tokenization of IUPAC names.
33
 
34
  The PubChem CIDs, SIDs, IULAC names of the considered small biomolecules, and their labels were taken from PubChem AID 686978 provided by the National Institutes of Health, PubChem, "qHTS for Inhibitors of Human Tyrosyl-DNA Phosphodiesterase 1 (TDP1): qHTS in Cells in Absence of CPT" https://pubchem.ncbi.nlm.nih.gov/bioassay/686978 , which contains 61,471 active compounds out of 424,003 small biomolecules.
35
 
36
  The inactive samples were reduced to 40,405 samples by merging the dataset above with the dataset of PubChem AID 1996 bioassay https://pubchem.ncbi.nlm.nih.gov/bioassay/1996 "Aqueous Solubility from MLSMR Stock Solutions", on CID, keeping only the common compounds for both bioassays.
37
-
 
14
 
15
  ## Dataset Details
16
 
17
+ This dataset had been leveraged for computations, such as:
18
+ - determine the most or least desirable functional group/fragment that would provide an insight for the development of TDP1 inhibitors
19
  - ML models based on IUPAC names broken down to functional names/fragments
20
+ - Define the feature importance of the above-mentioned ML model and explore the proportion between active and inactive compounds, which are the first 10 features
21
 
22
 
23
  ### Dataset Description
 
27
  It includes 3 columns:
28
  - Column 1: CID (PubChem identifiers of the compounds that are TDP1 inhibitors)
29
  - Column 2: SID (PubChem identifiers of the substances that are TDP1 inhibitors)
30
+ - Column 3: target: "1": The molecule is a TDP1 inhibitor; "0": The molecule is not a TDP1 inhibitor.
31
+ - Column 4: IUPAC names of the small biomolecules considered in the study.
32
  - Columns 5-5966: Functional groups/fragments of the small biomolecules considered in the study, which are the results of tokenization of IUPAC names.
33
 
34
  The PubChem CIDs, SIDs, IULAC names of the considered small biomolecules, and their labels were taken from PubChem AID 686978 provided by the National Institutes of Health, PubChem, "qHTS for Inhibitors of Human Tyrosyl-DNA Phosphodiesterase 1 (TDP1): qHTS in Cells in Absence of CPT" https://pubchem.ncbi.nlm.nih.gov/bioassay/686978 , which contains 61,471 active compounds out of 424,003 small biomolecules.
35
 
36
  The inactive samples were reduced to 40,405 samples by merging the dataset above with the dataset of PubChem AID 1996 bioassay https://pubchem.ncbi.nlm.nih.gov/bioassay/1996 "Aqueous Solubility from MLSMR Stock Solutions", on CID, keeping only the common compounds for both bioassays.